Monocyte CD49e and 110-120 kDa fibronectin fragments: HIV prognostic indicators independent of viral load and CD4 T-cell counts

AIDS

Volumn 23, Issue 17, 2009, Pages 2247-2253

  Rossen, Roger D ^a,b   Rubio, Jose A ^a,b   Porter, Wendy J ^a,b   Trial, Joann ^a,b   Orson, Frank M ^a,b   Rodriguez Barradas, Maria C ^a,b   Birdsall, Holly H ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cell binding 110 120 kDa fibronectin fragments; Inflammation; Monocytes; Patient survival; Protease antiprotease balance

Indexed keywords

ALPHA5 INTEGRIN; FIBRONECTIN;

ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; FLOW CYTOMETRY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MONOCYTE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; VIRUS LOAD; WESTERN BLOTTING;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOTTING, WESTERN; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; FEMALE; FIBRONECTINS; GENE EXPRESSION REGULATION; HIV INFECTIONS; HIV-1; HUMANS; INTEGRIN ALPHA5; MALE; MEDICATION ADHERENCE; MONOCYTES; PEPTIDE FRAGMENTS; PROGNOSIS; VIRAL LOAD;

EID: 70449375399     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283318ff4     Document Type: Article

References (30)

1. Weeks BS. The role of HIV-1 activated leukocyte adhesion mechanisms and matrix metalloproteinase secretion in AIDS pathogenesis (review). Int J Mol Med 1998; 1:361-366.
2. Schacker TW, Nguyen PL, Beilman GJ, Wolinsky S, Larson M, Reilly C, Haase AT. Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J Clin Invest 2002; 110:1133-1139.
3. Trial J, Rubio JA, Birdsall HH, Rodriguez-Barradas MC, Rossen RD. Monocyte activation by circulating fibronectin fragments in HIV-1-infected patients. J Immunol 2004; 173:2190-2198.
4. Zhang K, McQuibban GA, Silva C, Butler GS, Johnston JB, Holden J, et al. HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurode-generation. Nat Neurosci 2003; 6:1064-1071.
5. Birdsall HH, Porter WJ, Green DM, Rubio J, Trial J, Rossen RD. Impact of fibronectin fragments on the transendothelial migration of HIV-infected leukocytes and the development of subendothelial foci of infectious leukocytes. J Immunol 2004; 173:2746-2754.
6. Birdsall HH, Porter WJ, Trial J, Rossen RD. Monocytes stimulated by 110-kDa fibronectin fragments suppress proliferation of anti-CD3-activated T cells. J Immunol 2005; 175:3347-3353.
7. Birdsall HH, Siwak EB, Trial J, Rodriguez-Barradas MC, White AC, Weitgrefe S, et al. Transendothelial migration of leukocytes carrying infectious HIV-1: an indicator of adverse prognosis. AIDS 2002; 16:5-12.
8. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, et al. CD4R T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004; 200:749-759.
9. de Larranaga GF, Petroni A, Deluchi G, Alonso BS, Benetucci JA. Viral load and disease progression as responsible for en-dothelial activation and/or injury in human immunodeficiency virus-1-infected patients. Blood Coagul Fibrinolysis 2003; 14:15-18.
10. Kramer-Hammerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner R. Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res 2005; 111:194-213.
11. Trial J, Baughn RE, Wygant JN, McIntyre BW, Birdsall HH, Youker KA, et al. Fibronectin fragments modulate monocyte VLA-5 expression and monocyte migration. J Clin Invest 1999; 104:419-430.
12. Greco G, Pal S, Pasqualini R, Schnapp LM. Matrix fibronectin increases HIV stability and infectivity. J Immunol 2002; 168:5722-5729.
13. Trial J, Rossen RD, Rubio J, Knowlton AA. Inflammation and ischemia: macrophages activated by fibronectin fragments enhance the survival of injured cardiac myocytes. Exp Biol Med (Maywood) 2004; 229:538-545
14. CDC 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992 41 1-19
15. Escobar I, Campo M, Martin J, Fernandez-Shaw C, Pulido F, Rubio R. Factors affecting patient adherence to highly active antiretroviral therapy. Ann Pharmacother 2003; 37:775-781. (Pubitemid 36618359)
16. Torre D, Issi M, Sampietro C, Fiori GP, Chelazzi G, Ferraro G. Plasma fibronectin concentrations in patients with human immunodeficiency virus infection. J Clin Pathol 1990; 43:560-562.
17. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5:e203.
18. Beezhold DH, Personius C. Fibronectin fragments stimulate tumor necrosis factor secretion by human monocytes. J Leukoc Biol 1992; 51:59-64.
19. Marom B, Rahat MA, Lahat N, Weiss-Cerem L, Kinarty A, Bitterman H. Native and fragmented fibronectin oppositely modulate monocyte secretion of MMP-9. J Leukoc Biol 2007; 81:1466-1476.
20. Shoeman RL, Hartig R, Hauses C, Traub P. Organization of focal adhesion plaques is disrupted by action of the HIV-1 protease. Cell Biol Int 2002; 26:529-539.
21. Oswald M, von der Helm K. Fibronectin is a nonviral substrate for the HIV proteinase. FEBS Lett 1991; 292:298-300.
22. Bristow CL, Patel H, Arnold RR. Self antigen prognostic for human immunodeficiency virus disease progression. Clin Diagn Lab Immunol 2001; 8:937-942.
23. LarssonA, PalmM, Hansson LO, Basu S,Axelsson O.Reference values for alpha1-acid glycoprotein, alpha1-antitrypsin, albumin, haptoglobin, C-reactive protein, IgA, IgG and IgM during pregnancy. Acta Obstet Gynecol Scand 2008; 87:1084-1088.
24. Shapiro L, Pott GB, Ralston AH. Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1. FASEB J 2001; 15:115-122.
25. Cordelier P, Strayer DS. Conditional expression of alpha1-antitrypsin delivered by recombinant SV40 vectors protects lymphocytes against HIV. Gene Ther 2003; 10:2153-2156.
26. Congote LF. The C-terminal 26-residue peptide of serpin A1 is an inhibitor of HIV-1. Biochem Biophys Res Commun 2006; 343:617-622.
27. Mastrolorenzo A, Rusconi S, Scozzafava A, Barbaro G, Supuran CT. Inhibitors ofHIV-1 protease: current state of the art10years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors. Curr Med Chem 2007; 14:2734-2748.
28. Mastroianni CM, Liuzzi GM. Matrix metalloproteinase dysre-gulation in HIV infection: implications for therapeutic strategies. Trends Mol Med 2007; 13:449-459.
29. Fear G, Komarnytsky S, Raskin I. Protease inhibitors and their peptidomimetic derivatives as potential drugs. Pharmacol Ther 2007; 113:354-368.
30. McNeely TB, Shugars DC, Rosendahl M, Tucker C, Eisenberg SP, Wahl SM. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 1997; 90: 1141-1149